These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 27608846)

  • 1. STA-8666, a novel HSP90 inhibitor/SN-38 drug conjugate, causes complete tumor regression in preclinical mouse models of pediatric sarcoma.
    Heske CM; Mendoza A; Edessa LD; Baumgart JT; Lee S; Trepel J; Proia DA; Neckers L; Helman LJ
    Oncotarget; 2016 Oct; 7(40):65540-65552. PubMed ID: 27608846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HSP90 Inhibitor-SN-38 Conjugate Strategy for Targeted Delivery of Topoisomerase I Inhibitor to Tumors.
    Proia DA; Smith DL; Zhang J; Jimenez JP; Sang J; Ogawa LS; Sequeira M; Acquaviva J; He S; Zhang C; Khazak V; Astsaturov I; Inoue T; Tatsuta N; Osman S; Bates RC; Chimmanamada D; Ying W
    Mol Cancer Ther; 2015 Nov; 14(11):2422-32. PubMed ID: 26271675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Novel HSP90 Inhibitor-Drug Conjugate to SN38 Is Highly Effective in Small Cell Lung Cancer.
    Gaponova AV; Nikonova AS; Deneka A; Kopp MC; Kudinov AE; Skobeleva N; Khazak V; Ogawa LS; Cai KQ; Duncan KE; Duncan JS; Egleston BL; Proia DA; Boumber Y; Golemis EA
    Clin Cancer Res; 2016 Oct; 22(20):5120-5129. PubMed ID: 27267850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted delivery of chemotherapy using HSP90 inhibitor drug conjugates is highly active against pancreatic cancer models.
    Bobrov E; Skobeleva N; Restifo D; Beglyarova N; Cai KQ; Handorf E; Campbell K; Proia DA; Khazak V; Golemis EA; Astsaturov I
    Oncotarget; 2017 Jan; 8(3):4399-4409. PubMed ID: 27779106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of MM-398, nanoliposomal irinotecan (nal-IRI), in Ewing's family tumor xenografts is associated with high exposure of tumor to drug and high SLFN11 expression.
    Kang MH; Wang J; Makena MR; Lee JS; Paz N; Hall CP; Song MM; Calderon RI; Cruz RE; Hindle A; Ko W; Fitzgerald JB; Drummond DC; Triche TJ; Reynolds CP
    Clin Cancer Res; 2015 Mar; 21(5):1139-50. PubMed ID: 25733708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor-targeted SN38 inhibits growth of early stage non-small cell lung cancer (NSCLC) in a KRas/p53 transgenic mouse model.
    Deneka AY; Haber L; Kopp MC; Gaponova AV; Nikonova AS; Golemis EA
    PLoS One; 2017; 12(4):e0176747. PubMed ID: 28453558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended topoisomerase 1 inhibition through liposomal irinotecan results in improved efficacy over topotecan and irinotecan in models of small-cell lung cancer.
    Leonard SC; Lee H; Gaddy DF; Klinz SG; Paz N; Kalra AV; Drummond DC; Chan DC; Bunn PA; Fitzgerald JB; Hendriks BS
    Anticancer Drugs; 2017 Nov; 28(10):1086-1096. PubMed ID: 28857767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Irinotecan for pediatric solid tumors: the Memorial Sloan-Kettering experience.
    Cosetti M; Wexler LH; Calleja E; Trippett T; LaQuaglia M; Huvos AG; Gerald W; Healey JH; Meyers PA; Gorlick R
    J Pediatr Hematol Oncol; 2002 Feb; 24(2):101-5. PubMed ID: 11990694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of quercetin combined with anticancer drugs on metastasis-associated factors of gastric cancer cells: in vitro and in vivo studies.
    Lei CS; Hou YC; Pai MH; Lin MT; Yeh SL
    J Nutr Biochem; 2018 Jan; 51():105-113. PubMed ID: 29125991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.
    Na YS; Jung KA; Kim SM; Hong YS; Ryu MH; Jang SJ; Moon DH; Cho DH; Kim JC; Lee JS; Kim TW
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):389-98. PubMed ID: 21046105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current Role of Topoisomerase I Inhibitors for the Treatment of Mesenchymal Malignancies and Their Potential Future Use as Payload of Sarcoma-Specific Antibody-Drug Conjugates.
    Schöffski P; Wang CC; Schöffski MP; Wozniak A
    Oncol Res Treat; 2024; 47(1-2):18-41. PubMed ID: 38016427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BO-1055, a novel DNA cross-linking agent with remarkable low myelotoxicity shows potent activity in sarcoma models.
    Ambati SR; Shieh JH; Pera B; Lopes EC; Chaudhry A; Wong EW; Saxena A; Su TL; Moore MA
    Oncotarget; 2016 Jul; 7(28):43062-43075. PubMed ID: 27248664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective use of the single-mouse experimental design for the evaluation of PLX038A.
    Ghilu S; Li Q; Fontaine SD; Santi DV; Kurmasheva RT; Zheng S; Houghton PJ
    Cancer Chemother Pharmacol; 2020 Feb; 85(2):251-263. PubMed ID: 31927611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical results of camptothecin-polymer conjugate (IT-101) in multiple human lymphoma xenograft models.
    Numbenjapon T; Wang J; Colcher D; Schluep T; Davis ME; Duringer J; Kretzner L; Yen Y; Forman SJ; Raubitschek A
    Clin Cancer Res; 2009 Jul; 15(13):4365-73. PubMed ID: 19549776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of trabectedin and irinotecan is highly effective in a human rhabdomyosarcoma xenograft.
    Riccardi A; Meco D; Ubezio P; Mazzarella G; Marabese M; Faircloth GT; Jimeno J; D'Incalci M; Riccardi R
    Anticancer Drugs; 2005 Sep; 16(8):811-5. PubMed ID: 16096428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors.
    Houghton PJ; Cheshire PJ; Myers L; Stewart CF; Synold TW; Houghton JA
    Cancer Chemother Pharmacol; 1992; 31(3):229-39. PubMed ID: 1464161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of patient-derived xenograft engraftment in pediatric sarcomas.
    Castillo-Ecija H; Pascual-Pasto G; Perez-Jaume S; Resa-Pares C; Vila-Ubach M; Monterrubio C; Jimenez-Cabaco A; Baulenas-Farres M; Muñoz-Aznar O; Salvador N; Cuadrado-Vilanova M; Olaciregui NG; Balaguer-Lluna L; Burgueño V; Vicario FJ; Manzanares A; Castañeda A; Santa-Maria V; Cruz O; Celis V; Morales La Madrid A; Garraus M; Gorostegui M; Vancells M; Carrasco R; Krauel L; Torner F; Suñol M; Lavarino C; Mora J; Carcaboso AM
    J Pathol Clin Res; 2021 Jul; 7(4):338-349. PubMed ID: 33837665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors.
    Houghton PJ; Cheshire PJ; Hallman JD; Lutz L; Friedman HS; Danks MK; Houghton JA
    Cancer Chemother Pharmacol; 1995; 36(5):393-403. PubMed ID: 7634381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversion.
    Kalra AV; Kim J; Klinz SG; Paz N; Cain J; Drummond DC; Nielsen UB; Fitzgerald JB
    Cancer Res; 2014 Dec; 74(23):7003-13. PubMed ID: 25273092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The curative efficacy of namitecan (ST1968) in preclinical models of pediatric sarcoma is associated with antiangiogenic effects.
    Cassinelli G; Zuco V; Petrangolini G; De Cesare M; Tortoreto M; Lanzi C; Cominetti D; Zaffaroni N; Orlandi A; Passeri D; Meco D; Di Francesco AM; Riccardi R; Bucci F; Pisano C; Zunino F
    Biochem Pharmacol; 2012 Jul; 84(2):163-71. PubMed ID: 22525722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.